Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pucotenlimab + vorolanib
- Development stage
- Unknown
- Lead developer
- Lepu Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pucotenlimab + vorolanib is a combination therapy comprising a humanized IgG4 monoclonal antibody targeting the PD-1 receptor and a small molecule multi-kinase inhibitor. Pucotenlimab (HX008) acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated anti-tumor immunity. Vorolanib (CM082) is a tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), platelet-derived growth factor receptors (PDGFR), and c-Kit, effectively inhibiting tumor angiogenesis and cell proliferation. This combination is being investigated as a neoadjuvant treatment for patients with high-risk localized clear cell renal cell carcinoma (ccRCC) to reduce tumor complexity and facilitate nephron-sparing surgery (partial nephrectomy).
- Brand names
- Pu-You-NingFu-Ke-Hua
- Other names
- HX008 + CM082
02
Targets
FGFR2 (Keratinocyte growth factor receptor)FCGRT (Neonatal crystallizable fragment receptor)FLT3 (Fms related receptor tyrosine kinase 3)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on pucotenlimab + vorolanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pucotenlimab + vorolanib.